Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 306

1.

Clinical pharmacogenetics and potential application in personalized medicine.

Zhou SF, Di YM, Chan E, Du YM, Chow VD, Xue CC, Lai X, Wang JC, Li CG, Tian M, Duan W.

Curr Drug Metab. 2008 Oct;9(8):738-84. Review.

PMID:
18855611
2.

Polymorphism of human cytochrome P450 enzymes and its clinical impact.

Zhou SF, Liu JP, Chowbay B.

Drug Metab Rev. 2009;41(2):89-295. doi: 10.1080/03602530902843483. Review.

PMID:
19514967
3.

Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam.

Veiga MI, Asimus S, Ferreira PE, Martins JP, Cavaco I, Ribeiro V, Hai TN, Petzold MG, Björkman A, Ashton M, Gil JP.

Eur J Clin Pharmacol. 2009 Apr;65(4):355-63. doi: 10.1007/s00228-008-0573-8. Epub 2008 Nov 1.

PMID:
18979093
4.

Applications of CYP450 testing in the clinical setting.

Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA.

Mol Diagn Ther. 2013 Jun;17(3):165-84. doi: 10.1007/s40291-013-0028-5. Review.

5.

Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.

Deenen MJ, Cats A, Beijnen JH, Schellens JH.

Oncologist. 2011;16(6):820-34. doi: 10.1634/theoncologist.2010-0259. Epub 2011 May 31. Review.

6.

Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.

Bosch TM.

Methods Mol Biol. 2008;448:63-76. doi: 10.1007/978-1-59745-205-2_5. Review.

PMID:
18370231
7.

Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.

Ekhart C, Doodeman VD, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD.

Pharmacogenet Genomics. 2008 Jun;18(6):515-23. doi: 10.1097/FPC.0b013e3282fc9766.

PMID:
18496131
8.

Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.

Bosch TM, Meijerman I, Beijnen JH, Schellens JH.

Clin Pharmacokinet. 2006;45(3):253-85. Review.

PMID:
16509759
9.

Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.

Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmöller J, Frötschl R, Köpke K, Gerloff T, Chernov JN, Roots I.

Eur J Clin Pharmacol. 2003 Aug;59(4):303-12. Epub 2003 Jul 15.

PMID:
12879168
10.

[CYP2D6-, CYP2C9- and CYP2C19-based dose adjustments: when do they make sense?].

Seeringer A, Kirchheiner J.

Internist (Berl). 2008 Jul;49(7):877-83. doi: 10.1007/s00108-008-2125-9. Review. German.

PMID:
18551264
11.

Expanding role of pharmacogenomics in the management of cardiovascular disorders.

Yip VL, Pirmohamed M.

Am J Cardiovasc Drugs. 2013 Jun;13(3):151-62. doi: 10.1007/s40256-013-0024-5. Review.

PMID:
23579966
12.

Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1.

Ozawa S, Soyama A, Saeki M, Fukushima-Uesaka H, Itoda M, Koyano S, Sai K, Ohno Y, Saito Y, Sawada J.

Drug Metab Pharmacokinet. 2004 Apr;19(2):83-95. Review.

13.

[Individualization of drug therapy and pharmacogenetics].

Yamamoto I, Azuma J.

Nihon Rinsho. 1998 Mar;56(3):579-83. Review. Japanese.

PMID:
9549339
14.

Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid.

Choi HY, Bae KS, Cho SH, Ghim JL, Choe S, Jung JA, Jin SJ, Kim HS, Lim HS.

Pharmacogenet Genomics. 2015 Dec;25(12):595-608. doi: 10.1097/FPC.0000000000000176.

PMID:
26367500
15.
16.

Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes.

Fohner A, Muzquiz LI, Austin MA, Gaedigk A, Gordon A, Thornton T, Rieder MJ, Pershouse MA, Putnam EA, Howlett K, Beatty P, Thummel KE, Woodahl EL.

Pharmacogenet Genomics. 2013 Aug;23(8):403-14. doi: 10.1097/FPC.0b013e3283629ce9.

17.

Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.

Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Xanthi A, Tavridou A, Manolopoulos VG.

Fundam Clin Pharmacol. 2007 Aug;21(4):419-26.

PMID:
17635181
18.

Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects.

Matimba A, Del-Favero J, Van Broeckhoven C, Masimirembwa C.

Hum Genomics. 2009 Jan;3(2):169-90.

19.

Pharmacogenomics of tamoxifen therapy.

Brauch H, Mürdter TE, Eichelbaum M, Schwab M.

Clin Chem. 2009 Oct;55(10):1770-82. doi: 10.1373/clinchem.2008.121756. Epub 2009 Jul 2. Review.

20.

The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.

de Leon J, Susce MT, Murray-Carmichael E.

Mol Diagn Ther. 2006;10(3):135-51. Review.

PMID:
16771600

Supplemental Content

Support Center